Sisinni Antonio, Casenghi Matteo, Popolo Rubbio Antonio, Berni Andrea, Bedogni Francesco, Barbato Emanuele
Clinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy.
Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University of Rome "La Sapienza", 1035 Rome, Italy.
Rev Cardiovasc Med. 2023 Apr 26;24(5):128. doi: 10.31083/j.rcm2405128. eCollection 2023 May.
Pharmacological treatment is the cornerstone therapy of heart failure with reduced ejection fraction (HFrEF). In addition, several percutaneous techniques have been developed to treat symptomatic patients, with specific heart failure (HF) phenotypes (e.g., valvular heart disease) that require non-pharmacological treatment. Given their prognostic relevance, it is imperative to deliver high-level patient care. This review provides a clinical overview on the available data regarding transcatheter devices in the armamentarium of contemporary interventional cardiologists, focusing on the clinical and anatomical selection criteria.
药物治疗是射血分数降低的心力衰竭（HFrEF）的基石疗法。此外，已经开发了几种经皮技术来治疗有症状的患者，这些患者具有需要非药物治疗的特定心力衰竭（HF）表型（例如，心脏瓣膜病）。鉴于其预后相关性，提供高水平的患者护理势在必行。本综述概述了当代介入心脏病学家可用设备中有关经导管装置的现有数据，重点关注临床和解剖学选择标准。
